Zacks Investment Research Upgrades Fresenius Medical Care Corporation (FMS) to “Buy”

Zacks Investment Research upgraded shares of Fresenius Medical Care Corporation (NYSE:FMS) from a hold rating to a buy rating in a report released on Tuesday. The firm currently has $46.00 target price on the stock.

According to Zacks, “Fresenius Medical Care provides a range of products for both treatment modalities, hemmodialysis and peritoneal dialysis, and is a full service provider of dialysis care. They provide dialysis treatment and related laboratory and diagnostic services at more than 1,000 dialysis clinics. They manufacture a range of hemodialysis machines, dialyzers, peritoneal dialysis solutions and ancillary products. They have operations in approximately 100 countries. “

A number of other research analysts have also issued reports on FMS. DZ Bank AG reiterated a neutral rating on shares of Fresenius Medical Care Corporation in a research note on Monday, January 9th. J P Morgan Chase & Co reiterated a buy rating on shares of Fresenius Medical Care Corporation in a research note on Wednesday, December 14th. RBC Capital Markets reiterated a sector perform rating and issued a $44.00 target price (up from $41.00) on shares of Fresenius Medical Care Corporation in a research note on Tuesday, November 1st. Royal Bank Of Canada raised their target price on shares of Fresenius Medical Care Corporation from $41.00 to $44.00 and gave the company a sector perform rating in a research note on Tuesday, November 1st. Finally, HSBC Holdings plc reiterated a hold rating on shares of Fresenius Medical Care Corporation in a research note on Tuesday, October 18th. Six research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. Fresenius Medical Care Corporation presently has a consensus rating of Buy and an average price target of $45.50.

Analyst Recommendations for Fresenius Medical Care Corporation (NYSE:FMS)

Shares of Fresenius Medical Care Corporation (NYSE:FMS) opened at 41.08 on Tuesday. Fresenius Medical Care Corporation has a 1-year low of $38.05 and a 1-year high of $47.52. The firm has a market cap of $25.15 billion, a price-to-earnings ratio of 21.46 and a beta of 0.53. The company’s 50-day moving average is $41.13 and its 200 day moving average is $42.31.

COPYRIGHT VIOLATION WARNING: This article was originally posted by sleekmoney and is owned by of sleekmoney. If you are reading this article on another site, it was illegally stolen and reposted in violation of U.S. & international copyright & trademark legislation. The legal version of this article can be accessed at http://sleekmoney.com/zacks-investment-research-upgrades-fresenius-medical-care-corporation-fms-to-buy/1657465.html.

Several institutional investors have recently added to or reduced their stakes in FMS. Elkfork Partners LLC acquired a new position in Fresenius Medical Care Corporation during the fourth quarter worth approximately $631,000. Marshall Wace LLP acquired a new position in Fresenius Medical Care Corporation during the fourth quarter worth approximately $1,430,000. Trexquant Investment LP acquired a new position in Fresenius Medical Care Corporation during the fourth quarter worth approximately $215,000. Keybank National Association OH increased its position in Fresenius Medical Care Corporation by 2.5% in the fourth quarter. Keybank National Association OH now owns 44,327 shares of the company’s stock worth $1,871,000 after buying an additional 1,098 shares during the last quarter. Finally, Thornburg Investment Management Inc. acquired a new position in Fresenius Medical Care Corporation during the fourth quarter worth approximately $6,577,000. 2.52% of the stock is owned by institutional investors.

Fresenius Medical Care Corporation Company Profile

Fresenius Medical Care AG & Co KGaA (FMC AG & CO. KGAA) is a kidney dialysis company. The Company provides dialysis care and related services to persons suffering from end stage renal disease (ESRD), as well as other healthcare services. The Company operates through four segments: North America, Europe, Middle East, Africa (EMEA), Asia-Pacific and Latin America.

5 Day Chart for NYSE:FMS

Get a free copy of the Zacks research report on Fresenius Medical Care Corporation (FMS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

This story was originally published by sleekmoney (http://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at http://sleekmoney.com/zacks-investment-research-upgrades-fresenius-medical-care-corporation-fms-to-buy/1657465.html

Receive News & Ratings for Fresenius Medical Care Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius Medical Care Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

 

Leave a Reply

Your email address will not be published. Required fields are marked *